Results 221 to 230 of about 290,361 (291)

Distinct Effects of Complement C4A and C4B Copy Numbers in Systemic Sclerosis Serological and Clinical Subtypes

open access: yesArthritis &Rheumatology, EarlyView.
Objective Complement component 4 (C4), encoded by C4A and C4B within the major histocompatibility complex (MHC) on chromosome 6, regulates the immune response and clears immune complexes. The variable copy number (CN) of C4 genes and retroviral human endogenous retrovirus K (HERV‐K) element influence its function.
Javier Martínez‐López   +156 more
wiley   +1 more source

Multiple imputation methods: a case study of daily gold price. [PDF]

open access: yesPeerJ Comput Sci
Alrawajfi A   +4 more
europepmc   +1 more source

Romosozumab and Denosumab Combination Therapy After Denosumab in Postmenopausal Osteoporosis

open access: yesArthritis &Rheumatology, EarlyView.
Objective Transition from long‐term denosumab (Dmab) to parathyroid hormone‐analogs or romosozumab (Romo) might expose patients to the risk of the so‐called rebound phenomenon. Adding Romo to Dmab might represent an option in patients experiencing a fracture while on Dmab.
Giovanni Adami   +10 more
wiley   +1 more source

Per‐ and Polyfluoroalkyl Substances and Hand Osteoarthritis: Data From the Osteoarthritis Initiative

open access: yesArthritis &Rheumatology, EarlyView.
Objective To explore whether biologic levels of specific per‐ and polyfluoroalkyl substances (PFAS) and a mixture of PFAS—reflecting the overall effect and accounting for correlations among PFAS—relate to incident hand osteoarthritis (HOA) and progression.
Jeffrey B. Driban   +14 more
wiley   +1 more source

Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 Study

open access: yesArthritis &Rheumatology, EarlyView.
Objective The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate to severe systemic lupus erythematosus (SLE) activity, despite receiving standard therapy. Methods Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly
Susan Manzi   +12 more
wiley   +1 more source

Impact of Evolving Treatment Patterns on Interstitial Lung Disease Progression in Systemic Sclerosis Using the European Scleroderma Trials and Research Database

open access: yesArthritis &Rheumatology, EarlyView.
Objective The treatment landscape for systemic sclerosis‐associated interstitial lung disease (SSc‐ILD) has evolved with increasingly available immunosuppressive therapies (ISTs) and antifibrotic treatments. However, their real‐world use remains unclear.
Corrado Campochiaro   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy